Safety and efficacy of a novel 0.5% epinastine topical eyelid cream in allergic conjunctivitis: a phase 3 trial
Japanese Journal of Ophthalmology · 2024
DOI: 10.1007/s10384-024-01108-9 ↗Kurz gefasst
Klinische Studie (Phase III) in der Zeitschrift Japanese Journal of Ophthalmology, 2024. Verfasst von Hiroshi Fujishima und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, Tsurumi University School of Dental Medicine, 2-1-3 Tsurumi, Tsurumi-ku, Yokohama-shi, Kanagawa, 230-8501, Japan. fujish…. Hauptthemen laut MEDLINE: Conjunctivitis, Allergic, Dibenzazepines. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Santen Pharmaceutical Co., Ltd..
Abstract (Originalsprache)
Purpose
The high prevalence of allergic conjunctivitis in Japan necessitates novel, easy-to-use treatment options for prophylactic use. We evaluated the safety and efficacy of a newly-developed 0.5% epinastine topical eyelid cream to prevent the development of allergic conjunctivitis. Study design This was a phase 3, single-centre, double-masked, intra-patient randomised trial in asymptomatic adults (aged 20–65 years) with seasonal allergic conjunctivitis in Japan.
Methods
The left and right eyes of eligible patients were randomised to receive a topical application of either 0.5% epinastine cream (~ 30 mg per dose) to one eye or placebo cream to the other (on the outer skin of the upper and lower eyelids) after a conjunctival antigen challenge (CAC) test. Symptom severity was assessed up to 24 h post-treatment. Primary efficacy endpoints were mean ocular itching and conjunctival hyperaemia severity scores in each eye; safety endpoints included adverse events (AEs) and adverse drug reaction (ADRs).
Results
In total, 30 patients (60 eyes) were included in the study. The 0.5% epinastine topical eyelid cream reduced mean ocular itching scores (difference in least squares means ± standard error, − 1.12 ± 0.214; p < 0.0001) and mean conjunctival hyperaemia scores (− 0.54 ± 0.197; p = 0.0097) 24 h after treatment versus placebo. The 0.5% epinastine topical eyelid cream was well tolerated, with no AEs or ADRs reported.
Conclusion
With its novel route of administration, 0.5% epinastine topical eyelid cream may be considered a unique, easy-to-use, once-daily treatment option to prevent the onset of seasonal allergic conjunctivitis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Ophthalmology, Tsurumi University School of Dental Medicine, 2-1-3 Tsurumi, Tsurumi-ku, Yokohama-shi, Kanagawa, 230-8501, Japan. fujishima117@gmail.com.
- Division of Ophthalmology, Department of Visual Sciences, Nihon University School of Medicine, Tokyo, Japan.
Förderung
- Santen Pharmaceutical Co., Ltd.
Zitieren
APA
Fujishima, H., & Shoji, J. (2024). Safety and efficacy of a novel 0.5% epinastine topical eyelid cream in allergic conjunctivitis: a phase 3 trial. Japanese Journal of Ophthalmology. https://doi.org/10.1007/s10384-024-01108-9
Vancouver
Fujishima H, Shoji J. Safety and efficacy of a novel 0.5% epinastine topical eyelid cream in allergic conjunctivitis: a phase 3 trial. Japanese Journal of Ophthalmology. 2024. doi:10.1007/s10384-024-01108-9
BibTeX
@article{Fujishima2024,
author = {Fujishima, Hiroshi and Shoji, Jun},
title = {Safety and efficacy of a novel 0.5% epinastine topical eyelid cream in allergic conjunctivitis: a phase 3 trial},
journal = {Japanese Journal of Ophthalmology},
year = {2024},
doi = {10.1007/s10384-024-01108-9}
}
EUVIMED